ARTBIO
Philippe Dasse is currently the Chief of Technical Operations at ARTBIO, a position held since December 2023. Previously, Philippe served as the Head of Technical Operations for Research and Development at Novartis Oncology from April 2018 to November 2023, where responsibilities included establishing a ten-year strategic plan for technical operations to enhance the theranostic platform following Novartis's acquisition of Advanced Accelerator Applications. Philippe's extensive experience also includes a role as Director of Technical Operations at Advanced Accelerator Applications from November 2002 to October 2018, overseeing the development and launch of theragnostic radiopharmaceuticals globally. Earlier in the career, Philippe held various positions, including Deputy General Manager, Qualified Person, and European Qualified Person for Pharmacovigilance. Philippe's educational background includes an MBA from IMD, a Doctorate in Pharmacy from Université de Tours, and additional specialized qualifications in nuclear medicine and pharmaceutical quality.
This person is not in any offices
ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.